No Data
Zhejiang Jolly Pharmaceutical (300181.SZ): The first transfer of shares under the 2024 employee stock ownership plan has been completed through non-trade transfer.
On January 15th, Gelonghui reported that Zhejiang Jolly Pharmaceutical (300181.SZ) announced that as of the date of this announcement, the company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen branch of China Securities Depository and Clearing Co., Ltd. The 5.975 million shares of the company's stocks held by the company’s repurchase special securities account were transferred on January 14, 2025, through a non-trading transfer to "Zhejiang Jolly Pharmaceutical Co., Ltd. - 2024 Employee Stock Ownership Plan." The number of transferred shares accounts for 0.85% of the total share capital of the company as of the announcement date of the employee stock ownership plan draft, with a transfer price of 8.07 yuan per share.
Zhejiang Jolly Pharmaceutical (300181.SZ) granted 5.855 million shares of restricted stocks at a grant price of 8.07 yuan per share.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that the restricted stock incentive plan for 2024 stipulates the restrictions on stocks...
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin tablets are proposed to be selected for the national Chinese Patent Medicine procurement alliance's centralized purchasing.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that recently, the company and its controlling subsidiary Qinghai Zhuofeng Cordyceps Sinensis Pharmaceutical...
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin capsules have officially been launched for sale.
On December 24, Gelonghui reported that Zhejiang Jolly Pharmaceutical (300181.SZ) announced on the investor interaction platform that the company’s Bailin capsules have officially launched for sale.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
